Verteporfin

Identification

Name
Verteporfin
Accession Number
DB00460
Description

Verteporfin, marketed as Visudyne, is a benzoporphyrin derivative. It is used as a photosensitizer in photodynamic therapy to eliminate abnormal blood vessels in wet form macular degeneration. Verteporfin accumulates in these abnormal blood vessels and, when stimulated by nonthermal red light with a wavelength of 693 nm in the presence of oxygen, produces highly reactive short-lived singlet oxygen and other reactive oxygen radicals, resulting in local damage to the endothelium and blockage of the vessels.

Type
Small Molecule
Groups
Approved, Investigational
Structure
Thumb
Weight
Average: 718.7942
Monoisotopic: 718.30026434
Chemical Formula
C41H42N4O8
Synonyms
  • Verteporfin
  • Verteporfina
  • Vertéporfine
  • Verteporfinum
External IDs
  • BPD
  • BPD-MA
  • CL 318952
  • FF 18

Pharmacology

Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:
Machine Learning
Data Science
Drug Discovery
Accelerate your drug discovery research with our fully connected ADMET dataset
Learn more
Indication

For the treatment of patients with predominantly classic subfoveal choroidal neovascularization due to age-related macular degeneration, pathologic myopia or presumed ocular histoplasmosis syndrome. Verteporfin can also be used to destroy tumors.

Associated Conditions
Contraindications & Blackbox Warnings
Contraindications
Contraindications & Blackbox Warnings
With our commercial data, access important information on dangerous risks, contraindications, and adverse effects.
Learn more
Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
Learn more
Pharmacodynamics

Verteporfin, otherwise known as benzoporphyrin derivative, is a medication used in conjunction with laser treatment to eliminate the abnormal blood vessels in the eye associated with conditions such as the wet form of macular degeneration. Verteporfin accumulates in these abnormal blood vessels and, when stimulated by nonthermal red light with a wavelength of 693 nm in the presence of oxygen, produces highly reactive short-lived singlet oxygen and other reactive oxygen radicals, resulting in local damage to the endothelium and blockage of the vessels.

Mechanism of action

Verteporfin is transported in the plasma primarily by lipoproteins. Once verteporfin is activated by light in the presence of oxygen, highly reactive, short-lived singlet oxygen and reactive oxygen radicals are generated. Light activation of verteporfin results in local damage to neovascular endothelium, resulting in vessel occlusion. Damaged endothelium is known to release procoagulant and vasoactive factors through the lipo-oxygenase (leukotriene) and cyclo-oxygenase (eicosanoids such as thromboxane) pathways, resulting in platelet aggregation, fibrin clot formation and vasoconstriction. Verteporfin appears to somewhat preferentially accumulate in neovasculature, including choroidal neovasculature. However, animal models indicate that the drug is also present in the retina. As singlet oxygen and reactive oxygen radicals are cytotoxic, Verteporfin can also be used to destroy tumor cells.

Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism

Metabolized to a small extent to its diacid metabolite by liver and plasma esterases. NADPH-dependent liver enzyme systems (including the cytochrome P450 isozymes) do not appear to play a role in the metabolism of verteporfin.

Route of elimination

Elimination is by the fecal route, with less than 0.01% of the dose recovered in urine.

Half-life

Following intravenous infusion, verteporfin exhibits a bi-exponential elimination with a terminal elimination half-life of approximately 5-6 hours. Mild hepatic insufficiency increases half-life by approximately 20%.

Clearance
Not Available
Adverse Effects
Medicalerrors
Reduce medical errors
and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.
Learn more
Reduce medical errors & improve treatment outcomes with our adverse effects data
Learn more
Toxicity

Overdose of drug and/or light in the treated eye may result in nonperfusion of normal retinal vessels with the possibility of severe decrease in vision that could be permanent. An overdose of drug will also result in the prolongation of the period during which the patient remains photosensitive to bright light.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Aminolevulinic acidAminolevulinic acid may increase the photosensitizing activities of Verteporfin.
CarprofenCarprofen may increase the photosensitizing activities of Verteporfin.
ClofazimineClofazimine may increase the photosensitizing activities of Verteporfin.
CyproheptadineCyproheptadine may increase the photosensitizing activities of Verteporfin.
DabrafenibDabrafenib may increase the photosensitizing activities of Verteporfin.
FebuxostatFebuxostat may increase the photosensitizing activities of Verteporfin.
FosdenopterinFosdenopterin may increase the photosensitizing activities of Verteporfin.
HexaminolevulinateHexaminolevulinate may increase the photosensitizing activities of Verteporfin.
MethotrimeprazineMethotrimeprazine may increase the photosensitizing activities of Verteporfin.
MethoxsalenMethoxsalen may increase the photosensitizing activities of Verteporfin.
Interactions
Improve patient outcomes
Build effective decision support tools with the industry’s most comprehensive drug-drug interaction checker.
Learn more
Food Interactions
No interactions found.

Products

Products
Comprehensive & structured drug product info
From application numbers to product codes, connect different identifiers through our commercial datasets.
Learn more
Easily connect various identifiers back to our datasets
Learn more
International/Other Brands
Visudine (Novartis)
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
VisudynePowder, for solution15 mgIntravenousCheplapharm Arzneimittel Gmbh2000-06-26Not applicableCanada flag
VisudyneInjection, powder, lyophilized, for solution15 mg/1IntravenousBausch Health US LLC2000-04-12Not applicableUS flag
VisudyneInjection, powder, lyophilized, for solution2 mg/1mLIntravenousNovartis2000-04-142012-09-01US flag
VisudyneInjection, powder, for solution15 mgIntravenousCheplapharm Arzneimittel Gmb H2020-12-16Not applicableEU flag
VisudyneInjection, powder, lyophilized, for solution15 mg/1IntravenousQLT Ophthalmics, Inc.2000-04-12Not applicableUS flag

Categories

ATC Codes
S01LA01 — Verteporfin
Drug Categories
Classification
Not classified

Chemical Identifiers

UNII
WU713D62N9
CAS number
129497-78-5
InChI Key
YTZALCGQUPRCGW-MXVXOLGGSA-N
InChI
InChI=1S/C41H42N4O8/c1-9-23-20(2)29-17-34-27-13-10-26(39(49)52-7)38(40(50)53-8)41(27,5)35(45-34)19-30-22(4)25(12-15-37(48)51-6)33(44-30)18-32-24(11-14-36(46)47)21(3)28(43-32)16-31(23)42-29/h9-10,13,16-19,38,42,44H,1,11-12,14-15H2,2-8H3,(H,46,47)/b28-16-,29-17-,30-19-,31-16-,32-18-,33-18-,34-17-,35-19-/t38-,41+/m0/s1
IUPAC Name
3-[(23S,24R)-14-ethenyl-5-(3-methoxy-3-oxopropyl)-22,23-bis(methoxycarbonyl)-4,10,15,24-tetramethyl-25,26,27,28-tetraazahexacyclo[16.6.1.1³,⁶.1⁸,¹¹.1¹³,¹⁶.0¹⁹,²⁴]octacosa-1,3,5,7,9,11(27),12,14,16,18(25),19,21-dodecaen-9-yl]propanoic acid
SMILES
COC(=O)CCC1=C2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(CCC(O)=O)=C5C)C(C=C)=C4C)C2=CC=C([C@@H](C(=O)OC)[C@@]32C)C(=O)OC)=C1C

References

General References
  1. Chan WM, Lim TH, Pece A, Silva R, Yoshimura N: Verteporfin PDT for non-standard indications--a review of current literature. Graefes Arch Clin Exp Ophthalmol. 2010 May;248(5):613-26. doi: 10.1007/s00417-010-1307-z. Epub 2010 Feb 17. [PubMed:20162298]
  2. Nowak-Sliwinska P, Karocki A, Elas M, Pawlak A, Stochel G, Urbanska K: Verteporfin, photofrin II, and merocyanine 540 as PDT photosensitizers against melanoma cells. Biochem Biophys Res Commun. 2006 Oct 20;349(2):549-55. Epub 2006 Aug 22. [PubMed:16945338]
Human Metabolome Database
HMDB0014603
KEGG Drug
D01162
PubChem Compound
5362420
PubChem Substance
46506236
ChemSpider
4515032
RxNav
118886
ChEMBL
CHEMBL2052016
PharmGKB
PA451871
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Verteporfin
AHFS Codes
  • 52:92.00 — EENT Drugs, Miscellaneous
FDA label
Download (39.2 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedTreatmentAge-Related Macular Degeneration (ARMD)2
4CompletedTreatmentAge-Related Macular Degeneration (ARMD) / Polypoidal Choroidal Vasculopathy (PCV)1
4CompletedTreatmentMaculopathies, Age-Related / Subfoveal Choroidal Neovascularization1
4CompletedTreatmentPolypoidal Choroidal Vasculopathy (PCV)1
4Not Yet RecruitingTreatmentExudative Age Related Macular Degeneration / Neovascular Age-Related Macular Degeneration1
4TerminatedTreatmentAge-Related Macular Degeneration (ARMD)1
3CompletedTreatmentAge Related Macular Degeneration (ARMD) / Age-Related Macular Degeneration (ARMD)1
3CompletedTreatmentAge-Related Macular Degeneration (ARMD) / Subfoveal Choroidal Neovascularization1
3CompletedTreatmentMacular Degeneration2
3CompletedTreatmentMacular Degeneration / Subfoveal Choroidal Neovascularization2

Pharmacoeconomics

Manufacturers
  • Qlt inc
Packagers
  • Hollister-Stier Laboratories LLC
  • JHP Pharmaceuticals LLC
  • Novartis AG
  • QLT Inc.
Dosage Forms
FormRouteStrength
Injection, powder, for solutionIntravenous
Injection, powder, for solutionIntravenous15 mg
Injection, powder, lyophilized, for solutionIntravenous15 mg/1
Injection, powder, lyophilized, for solutionIntravenous2 mg/1mL
Powder, for solutionIntravenous15 mg
Powder, for solutionIntravenous; Parenteral
Prices
Unit descriptionCostUnit
Visudyne 15 mg vial1702.64USD vial
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)Region
US5214036No1993-05-252010-05-25US flag
CA2536069No2008-06-032014-03-14Canada flag
CA1339927No1998-06-232015-06-23Canada flag
US5756541No1998-05-262016-03-11US flag
US5798349No1998-08-252015-08-25US flag
US5707608No1998-01-132015-08-02US flag

Properties

State
Solid
Experimental Properties
PropertyValueSource
logP2.1Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0136 mg/mLALOGPS
logP5.02ALOGPS
logP6.34ChemAxon
logS-4.7ALOGPS
pKa (Strongest Acidic)4.12ChemAxon
pKa (Strongest Basic)4.78ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area173.56 Å2ChemAxon
Rotatable Bond Count12ChemAxon
Refractivity199.08 m3·mol-1ChemAxon
Polarizability81.29 Å3ChemAxon
Number of Rings6ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption-0.5377
Blood Brain Barrier+0.6313
Caco-2 permeable-0.6425
P-glycoprotein substrateSubstrate0.7738
P-glycoprotein inhibitor INon-inhibitor0.577
P-glycoprotein inhibitor IINon-inhibitor0.5444
Renal organic cation transporterNon-inhibitor0.7681
CYP450 2C9 substrateNon-substrate0.8178
CYP450 2D6 substrateNon-substrate0.822
CYP450 3A4 substrateSubstrate0.6429
CYP450 1A2 substrateInhibitor0.7915
CYP450 2C9 inhibitorInhibitor0.7158
CYP450 2D6 inhibitorNon-inhibitor0.754
CYP450 2C19 inhibitorNon-inhibitor0.7057
CYP450 3A4 inhibitorNon-inhibitor0.5157
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.652
Ames testNon AMES toxic0.6596
CarcinogenicityNon-carcinogens0.9368
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.6756 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9884
hERG inhibition (predictor II)Non-inhibitor0.9038
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created on June 13, 2005 13:24 / Updated on April 11, 2021 00:58